Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus

PHASE3CompletedINTERVENTIONAL
Enrollment

302

Participants

Timeline

Start Date

March 15, 2017

Primary Completion Date

July 4, 2018

Study Completion Date

August 6, 2018

Conditions
DiabetesDiabetes Mellitus, Type 2
Interventions
DRUG

Semaglutide

Semaglutide, gradually increased to 1.0 mg, injected once weekly under the skin (subcutaneously, s.c.) for 30 weeks

DRUG

Placebo

Semaglutide placebo, gradually increased to 1.0 mg, injected once weekly under the skin (subcutaneously, s.c.) for 30 weeks

Trial Locations (72)

1030

Novo Nordisk Investigational Site, Vienna

1060

Novo Nordisk Investigational Site, Vienna

1130

Novo Nordisk Investigational Site, Vienna

2317

Novo Nordisk Investigational Site, Hamar

3515

Novo Nordisk Investigational Site, Hoenefoss

4005

Novo Nordisk Investigational Site, Stavanger

7801

Novo Nordisk Investigational Site, Namsos

8511

Novo Nordisk Investigational Site, Saint Stefan

11787

Novo Nordisk Investigational Site, Smithtown

12206

Novo Nordisk Investigational Site, Albany

14224

Novo Nordisk Investigational Site, West Seneca

15009

Novo Nordisk Investigational Site, Beaver

15243

Novo Nordisk Investigational Site, Pittsburgh

15317

Novo Nordisk Investigational Site, McMurray

21204

Novo Nordisk Investigational Site, Baltimore

23321

Novo Nordisk Investigational Site, Chesapeake

27834

Novo Nordisk Investigational Site, Greenville

28054

Novo Nordisk Investigational Site, Gastonia

28207

Novo Nordisk Investigational Site, Charlotte

28226

Novo Nordisk Investigational Site, Charlotte

28501

Novo Nordisk Investigational Site, Kinston

30046

Novo Nordisk Investigational Site, Lawrenceville

32132

Novo Nordisk Investigational Site, Edgewater

36207

Novo Nordisk Investigational Site, Anniston

36420

Novo Nordisk Investigational Site, Andalusia

40503

Novo Nordisk Investigational Site, Lexington

48098

Novo Nordisk Investigational Site, Troy

65109

Novo Nordisk Investigational Site, Jefferson City

72211

Novo Nordisk Investigational Site, Little Rock

73069

Novo Nordisk Investigational Site, Norman

75208

Novo Nordisk Investigational Site, Dallas

75231

Novo Nordisk Investigational Site, Dallas

77081

Novo Nordisk Investigational Site, Houston

77479

Novo Nordisk Investigational Site, Sugar Land

77901

Novo Nordisk Investigational Site, Victoria

78231

Novo Nordisk Investigational Site, Shavano Park

78745

Novo Nordisk Investigational Site, Austin

84123

Novo Nordisk Investigational Site, Murray

85037

Novo Nordisk Investigational Site, Phoenix

85283

Novo Nordisk Investigational Site, Tempe

85308

Novo Nordisk Investigational Site, Glendale

91325

Novo Nordisk Investigational Site, Northridge

92037

Novo Nordisk Investigational Site, La Jolla

95648

Novo Nordisk Investigational Site, Lincoln

98502

Novo Nordisk Investigational Site, Olympia

191119

Novo Nordisk Investigational Site, Saint Petersburg

194354

Novo Nordisk Investigational Site, Saint Petersburg

194358

Novo Nordisk Investigational Site, Saint Petersburg

630099

Novo Nordisk Investigational Site, Novosibirsk

656045

Novo Nordisk Investigational Site, Barnaul

32751-4422

Novo Nordisk Investigational Site, Maitland

30189-4255

Novo Nordisk Investigational Site, Woodstock

67502-1131

Novo Nordisk Investigational Site, Hutchinson

28557-4346

Novo Nordisk Investigational Site, Morehead City

76012-4637

Novo Nordisk Investigational Site, Arlington

75061-2210

Novo Nordisk Investigational Site, Irving

T6H 2L4

Novo Nordisk Investigational Site, Edmonton

R3E 3P4

Novo Nordisk Investigational Site, Winnipeg

L6S 0C6

Novo Nordisk Investigational Site, Brampton

L6T 0G1

Novo Nordisk Investigational Site, Brampton

M9R 4E1

Novo Nordisk Investigational Site, Etobicoke

K7A 4W8

Novo Nordisk Investigational Site, Smiths Falls

M5T 3L9

Novo Nordisk Investigational Site, Toronto

N2J 1C4

Novo Nordisk Investigational Site, Waterloo

232-0064

Novo Nordisk Investigational Site, Kanagawa

480-1195

Novo Nordisk Investigational Site, Nagakute-shi, Aichi

565-0853

Novo Nordisk Investigational Site, Suita-shi, Osaka

160-0008

Novo Nordisk Investigational Site, Tokyo

0953

Novo Nordisk Investigational Site, Olso

0176

Novo Nordisk Investigational Site, Oslo

NO-2020

Novo Nordisk Investigational Site, Skedsmokorset

00716

Novo Nordisk Investigational Site, Ponce

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT03086330 - Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter